When to start antiretroviral therapy? NA-accord stimulates the debate

AIDS Reader

Volumn 19, Issue 2, 2009, Pages

  Gallant, Joel E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretroviral therapy; Conference coverage; HIV AIDS; Treatment guidelines

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; VIRUS RNA;

CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COHORT ANALYSIS; DRUG EFFICACY; DRUG INDICATION; EARLY DIAGNOSIS; EDITORIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL DECISION MAKING; MORTALITY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; RISK BENEFIT ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME; BLOOD; DRUG ADMINISTRATION; FEMALE; MIDDLE AGED; ORGANIZATION; PREGNANCY; VIRUS LOAD;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CONGRESSES AS TOPIC; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HUMANS; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; RNA, VIRAL; VIRAL LOAD;

EID: 62249181620     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (12)

1. Kitahata MM, Gange SJ, Moore RD. Initiating rather than deferring HAART at a CD4 count between 351-500 cells/mm3 is associated with improved survival. 48th Annual ICAAC/IDSA 46th Annual Meeting; October 25-28,2008; Washington, DC. Abstract H-896b.
2. May M, Sterne JA, Sabin C, et al; Antiretroviral Therapy (ART) Cohort Collaboration. Prognosis of HIV-l-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS. 2007;21:1185-1197.
3. Marin B, Thiebaut R, Rondeau V, et al. Association between CD4 and HIV RNA with non-AIDS-related causes of death in the era of combination antiretroviral therapy (cART). 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 22-25,2007; Sydney, Australia. Abstract WEPEB019.
4. Bruyard M, Thiebaut R, Lawson-Ayayi S, et al. Immunodeficiency and risk of AIDS-defining and non-AIDS-defining cancers: ANRS C03 Aquitaine cohort, 1998 to 2006.15th Conference on Retroviruses and Opportunistic Infections; February 3-6,2008; Boston. Abstract 15.
5. 3compared with the general population. 15th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston. Abstract 141.
6. 3 does not increase incidence or risk of peripheral neuropathy, anemia, or renal insufficiency. J Acquir Immune Defk Syndr. 2008;47:27-35.
7. 3 or greater. J Acquir Immune Defic Syndr. 2007; 45:183-192.
8. + cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis. 2007;44:441-446.
9. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-l-infected adults and adolescents. Department of Health and Human Services. November 3, 2008;1-139. http://www. aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed December 15,2008.
10. Hammer SM, Eron JJ Jr, Reiss P, et al; International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008;300:555-570.
11. Strategies for Management of Antiretroviral Therapy (SMART) Study Group. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART atbaseline in the SMART study. J Infect Dis.2008;197:1133-1144.
12. Granich RM, Gilks CF, Dye C, et al. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373:48-57.